For achievement of
FIRM VISION 2025
- Ideals to be
realized by 2025
- Realize systems that are appropriate for regenerative medicine.
- Realize increase in products and commercialization.
- Enhance international competitiveness of Japan.
- Strengthen the management foundation of FIRM.
- Ideal form which will be
realized by 2021
- Organize issues from creation to launch of product. Go on discussion with administration.
- Newly build function to make public comment, as well as improve quality of information which we dispatch.
- Cell and Gene Therapy Products Committee will be established in Central Social Insurance Medical Council. Price based on characteristics of product will be considered.
- Policies for reduction of cost of cell and gene therapy products will be implemented.
- Empower and enlarge relationship with administration, media and members of the National Diet. Increase the amount of information that FIRM will dispatch.
- Establish model of cooperation with academia, industry, administration and VC. Support them by offering necessary information and know-how.
- Recognition of each guide will be boosted. Activate engagement- strengthening between the supporting industry companies and product creating companies.
- Toward regulatory harmonization, give comments on problem solutions to regulatory authorities in Asian nations and regions.
- Strengthen cooperation with foreign company organization, and support FIRM companies in their international expansion and their international cooperation with foreign companies.
- Government and people of Japan will be collaborating and show more presence in regenerative medical world in Japan.
- Role of international standard in regenerative medicine will be realized in and outside of FIRM.
- Collaborate with European and American relative organizations in order to realize international standardization of pre-clinical test. Accumulate the evaluation results.
VC: Venture Capital